Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide in post-docetaxel mCRPC
NCT00974311Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2009
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Enzalutamide with Placebo (2 arms). Primary endpoint: Overall Survival up to 101 months. Started Sep 2009; status: completed.
02
Drugs
enzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00974311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00974311.